SCF-SEP-MNSS-TEMP-0005
SCF Disease Progression Timeline Mapping
Sepsis-Induced Encephalopathy
Therapeutic Temporal Windows Mapped to SCF Multi-Neurosystems Shock States (MNSS)
Integrated Neuroimmune, Neurocardiac, Neurovascular, Neurometabolic, and Neuroendocrine Shock-State Architecture
Pre-Encephalopathy → Septic Encephalopathy → Post-Encephalopathy Reconstruction
I. SCF SEPTIC ENCEPHALOPATHY SHOCK CASCADE
Primary Pathogenic Flow
Pathogen Exposure
↓
Innate Immune Activation
↓
Systemic Inflammatory Response
↓
Endothelial Injury
↓
BBB Dysfunction
↓
Microglial Activation
↓
Neuroimmune Propagation
↓
Neurovascular Failure
↓
Neurometabolic Collapse
↓
Neuroaxonal Injury
↓
Connectomic Collapse
↓
Septic Encephalopathy
↓
Post-Sepsis Neurocognitive Syndrome
II. MASTER TEMPORAL PROGRESSION TABLE
SCF Phase | Temporal Window | Dominant Shock State | Clinical Status | Reversibility |
MNSS-0 | Weeks–Years Before Infection | Compensated State | Healthy | Very High |
MNSS-IA | Hours–Days After Infection | Neuroimmune Priming | Infection without CNS symptoms | Very High |
MNSS-IB | 24–48 Hours | Neuroimmune-Neurovascular Shock | Brain fog, fatigue | Very High |
MNSS-II | 24–72 Hours Before Delirium | Neurovascular-Neuroglial Shock | Cognitive fluctuation | High |
MNSS-IIIA | Hours–Days After Delirium | Neuroglial Shock | Early SAE | High |
MNSS-IIIB | Days–Weeks | Neuroaxonal Shock | Established SAE | Moderate |
MNSS-IV | Hours–Days | Global Multi-Neurosystems Shock | Severe SAE | Limited |
MNSS-R1 | Days–Weeks | Resolution State | Recovery initiation | High |
MNSS-R2 | Weeks–Months | Connectomic Reconstruction | Cognitive recovery | Moderate–High |
MNSS-R3 | Months–Years | Neuroadaptive State | Post-sepsis syndrome | Variable |
III. PRE-ENCEPHALOPATHY THERAPEUTIC WINDOWS
WINDOW 1
MNSS-IA — SYSTEMIC INFECTION PRIMING
Temporal Window
0–48 Hours After Infection
Dominant SCF Shock States
- Neuroimmune Shock (NIS-1)
- Neurocardiac Shock (NCS-1)
Neuroimmune Biomarkers
Biomarker | Baseline | Alert Threshold |
IL-6 | <2 pg/mL | >10 pg/mL |
TNF-α | <5 pg/mL | >10 pg/mL |
IL-8 | <10 pg/mL | >20 pg/mL |
CRP | <5 mg/L | >20 mg/L |
PCT | <0.05 ng/mL | >0.5 ng/mL |
Neurocardiac Biomarkers
Biomarker | Baseline | Alert Threshold |
HRV SDNN | >100 ms | <90 ms |
RMSSD | >30 ms | <25 ms |
LF/HF Ratio | 1–2 | >3 |
Clinical Status
- Fever
- Malaise
- Sleep disruption
Therapeutic Objective
Prevent CNS propagation
WINDOW 2
MNSS-IB — EARLY NEUROIMMUNE PROPAGATION
Temporal Window
24–72 Hours
Dominant SCF Shock States
- Neuroimmune Shock (NIS-2)
- Neurovascular Shock (NVS-1)
- Neuroendocrine Shock (NES-1)
Neuroimmune Biomarkers
Biomarker | Alert Threshold |
IL-6 | >20 pg/mL |
TNF-α | >15 pg/mL |
HMGB1 | >5 ng/mL |
CXCL10 | Elevated |
Neurovascular Biomarkers
Biomarker | Alert Threshold |
Angiopoietin-2 | >5000 pg/mL |
Syndecan-1 | >50 ng/mL |
ICAM-1 | Elevated |
VCAM-1 | Elevated |
Neuroendocrine Biomarkers
Biomarker | Alert Threshold |
Cortisol | >25 µg/dL |
ACTH | Elevated |
Vasopressin | Elevated |
Early Symptoms
- Fatigue
- Brain fog
- Reduced attention
- Circadian disruption
Therapeutic Objective
Prevent BBB injury
IV. PRE-ENCEPHALOPATHIC SEPTIC BRAIN INJURY
WINDOW 3
MNSS-II
Temporal Window
24–72 Hours Before Delirium
Dominant Shock States
- Neurovascular Shock (NVS-2)
- Neuroglial Shock (NGS-1)
- Neurometabolic Shock (NMS-1)
Neurovascular Biomarkers
Biomarker | Threshold |
MMP-9 | >250 ng/mL |
S100B | >0.15 ng/mL |
Claudin-5 Fragments | Detectable |
Occludin Fragments | Detectable |
Neuroglial Biomarkers
Biomarker | Threshold |
GFAP | >150 pg/mL |
YKL-40 | >100 ng/mL |
sTREM2 | Elevated |
Neurometabolic Biomarkers
Biomarker | Threshold |
Lactate | >2 mmol/L |
Lactate/Pyruvate Ratio | >25 |
cf-mtDNA | Elevated |
ATP Production | ↓20–30% |
Clinical Features
- Sleep inversion
- Mild confusion
- Slowed cognition
Therapeutic Objective
Prevent neuroaxonal injury
V. EARLY SEPTIC ENCEPHALOPATHY
WINDOW 4
MNSS-IIIA
Temporal Window
Hours–Days Following Delirium Onset
Dominant Shock States
- Neuroglial Shock (NGS-2)
- Neuroimmune Shock (NIS-3)
Neuroimmune Biomarkers
Biomarker | Threshold |
IL-6 | >50 pg/mL |
TNF-α | >25 pg/mL |
HMGB1 | >10 ng/mL |
Neuroglial Biomarkers
Biomarker | Threshold |
GFAP | >250 pg/mL |
S100B | >0.2 ng/mL |
YKL-40 | >150 ng/mL |
Connectomic Biomarkers
Biomarker | Threshold |
EEG Delta Power | Increased |
EEG Theta Power | Increased |
qEEG Connectivity | >15% decline |
Clinical Features
- Delirium
- Agitation
- Inattention
- Cognitive instability
Therapeutic Objective
Preserve network integrity
VI. ESTABLISHED SEPTIC ENCEPHALOPATHY
WINDOW 5
MNSS-IIIB
Temporal Window
Days–Weeks
Dominant Shock States
- Neuroaxonal Shock (NAS-1)
- Neurocardiac Shock (NCS-2)
- Neurometabolic Shock (NMS-2)
Neuroaxonal Biomarkers
Biomarker | Threshold |
NfL | >20 pg/mL |
UCH-L1 | Elevated |
NSE | Elevated |
Total Tau | Elevated |
Neurocardiac Biomarkers
Biomarker | Threshold |
SDNN | <80 ms |
RMSSD | <15 ms |
Troponin | Elevated |
NT-proBNP | Elevated |
Neurometabolic Biomarkers
Biomarker | Threshold |
Lactate | >4 mmol/L |
ATP Production | ↓40% |
cf-mtDNA | High |
Clinical Features
- Persistent delirium
- Executive dysfunction
- Dysautonomia
Therapeutic Objective
Stabilize connectomic collapse
VII. ACUTE MULTI-NEUROSYSTEMS SHOCK
WINDOW 6
MNSS-IV
Temporal Window
Hours–Days
Dominant Shock States
- Neuroimmune Shock (NIS-4)
- Neurocardiac Shock (NCS-3)
- Neurovascular Shock (NVS-3)
- Neurometabolic Shock (NMS-3)
- Neuroendocrine Shock (NES-3)
Peak Biomarker Panel
System | Biomarkers |
Neuroimmune | IL-6, TNF-α, HMGB1, IL-8 |
Neurocardiac | SDNN <50 ms, Troponin, NT-proBNP |
Neurovascular | Ang-2, Syndecan-1, MMP-9 |
Neurometabolic | Lactate >5 mmol/L, cf-mtDNA |
Neuroendocrine | Cortisol dysregulation, ACTH dysregulation |
Neuroglial | GFAP peak, YKL-40 peak |
Neuroaxonal | NfL peak, UCH-L1 peak |
Clinical Features
- Severe encephalopathy
- Septic shock
- Coma
- Respiratory failure
- Seizures
Therapeutic Objective
Life preservation
Organ support
VIII. POST-ENCEPHALOPATHY RECOVERY WINDOWS
WINDOW 7
MNSS-R1 — SHOCK RESOLUTION
Temporal Window
Days–Weeks
Dominant State
Controlled inflammatory resolution
Recovery Biomarkers
Biomarker | Recovery Trend |
IL-6 | ↓ |
TNF-α | ↓ |
HMGB1 | ↓ |
Lactate | ↓ |
Ang-2 | ↓ |
Syndecan-1 | ↓ |
Therapeutic Objective
Accelerate recovery
WINDOW 8
MNSS-R2 — CONNECTOMIC RECONSTRUCTION
Temporal Window
Weeks–Months
Dominant State
Network reintegration
Reconstruction Biomarkers
Biomarker | Desired Trend |
GFAP | ↓ |
NfL | ↓ |
qEEG Connectivity | ↑ |
DTI FA | ↑ |
HRV SDNN | ↑ |
Cortisol Rhythm | Normalizing |
Therapeutic Objective
Restore cognition
Restore autonomic function
WINDOW 9
MNSS-R3 — POST-SEPSIS NEUROCOGNITIVE SYNDROME
Temporal Window
Months–Years
Dominant State
Neuroadaptive compensation
Persistent Risk Biomarkers
System | Biomarkers |
Neuroimmune | HMGB1, IL-6, YKL-40 |
Neurocardiac | Persistent SDNN suppression |
Neurovascular | Residual endothelial dysfunction |
Neurometabolic | Mitochondrial inefficiency |
Neuroendocrine | Cortisol rhythm loss |
Neuroglial | GFAP |
Neuroaxonal | NfL, Tau |
Connectomic | qEEG dysconnectivity |
Clinical Features
- Post-sepsis cognitive impairment
- Brain fog
- Dysautonomia
- Sleep dysfunction
- Fatigue syndrome
IX. MASTER SCF SEPTIC ENCEPHALOPATHY BIOMARKER MATRIX
Temporal Phase | Neuroimmune | Neurocardiac | Neurovascular | Neurometabolic | Neuroendocrine |
MNSS-IA | IL-6, CRP, PCT | SDNN ↓ | Ang-2 ↑ | L/P Ratio ↑ | Cortisol ↑ |
MNSS-IB | HMGB1, CXCL10 | LF/HF ↑ | Syndecan-1 ↑ | cf-mtDNA ↑ | ACTH ↑ |
MNSS-II | IL-6 ↑↑ | SDNN ↓↓ | MMP-9, S100B | Lactate ↑ | Vasopressin ↑ |
MNSS-IIIA | Cytokine Surge | HRV Collapse | BBB Injury | ATP Loss | HPA Activation |
MNSS-IIIB | Persistent Inflammation | Troponin ↑ | Endotheliopathy | Lactate ↑↑ | Circadian Loss |
MNSS-IV | Peak Cytokines | Severe Dysautonomia | Peak Endothelial Injury | Peak Metabolic Failure | HPA Collapse |
MNSS-R1 | Resolution | HRV Recovery | Endothelial Repair | Lactate Normalization | Partial Recovery |
MNSS-R2 | Low Inflammation | SDNN ↑ | BBB Repair | ATP Recovery | Rhythm Restoration |
MNSS-R3 | Residual Inflammation | Persistent HRV Abnormalities | Residual Dysfunction | Chronic Bioenergetic Deficits | Endocrine Adaptation |
X. SCF HIGHEST-VALUE THERAPEUTIC WINDOWS
Rank | Window | SCF Phase | Reversibility |
1 | Neuroimmune Priming | MNSS-IA | Very High |
2 | Early Neuroimmune Propagation | MNSS-IB | Very High |
3 | Pre-Encephalopathic Brain Injury | MNSS-II | High |
4 | Early SAE | MNSS-IIIA | High |
5 | Established SAE | MNSS-IIIB | Moderate |
6 | Acute Shock | MNSS-IV | Limited |
7 | Reconstruction | MNSS-R2 | Moderate–High |
MASTER REGISTRY INDEX
- SCF-SEP-MNSS-TEMP-0005 — Sepsis-Induced Encephalopathy Disease Progression Timeline Mapping
- SCF-ECCA-SEP-0001 — Septic Encephalopathy Module
- SCF-MNSS-0001 — Multi-Neurosystems Shock State Framework
- SCF-ECCA-SEP-BIO-0005 — Septic Encephalopathy Biomarker Panel
- SCF-CONNECTOMIC-RECONSTRUCTION-0001 — Neuroimmune Connectomic Reconstruction Framework
- SCF-BIOMARKER-ENDPOINTS-0001 — Biomarker Endpoint Validation Framework
- SCF-PATH-PROT-0001 — SCF Pathophysiology Protocol
- SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema